About
Abionbio develops a novel cancer immunotherapy platform called iRAC that selectively delivers engineered IFN-β mutein to tumor microenvironments, combining direct tumor cell killing and immune activation for targeted anticancer treatment.
Explore Abionbio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.